文献速递消化道肿瘤放疗胸部肿瘤放疗

短期疗效可能影响食管鳞癌同步放化疗后辅助化疗的治疗获益

Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients.
PubMed 文献 · Radiat Oncol · 2021-10-02

本研究回顾性分析了244例接受同步放化疗的II-IVa期食管鳞癌患者,比较同步放化疗联合辅助化疗组与单纯同步放化疗组的生存差异。倾向评分匹配后两组总生存和无进展生存均无显著差异,但短期疗效好的亚组接受辅助化疗后无进展生存更优,提示短期疗效可能有助于筛选辅助化疗获益人群。

要点

  • 倾向评分匹配后,辅助化疗未显著改善全部食管鳞癌患者的总生存和无进展生存。
  • 短期疗效好的亚组接受辅助化疗后无进展生存更优(HR=0.542,95%CI 0.336-0.876,P=0.008)。
  • 短期疗效对辅助化疗获益的独立预测作用经多因素Cox回归分析确认。

核心结论

  • 辅助化疗未显著改善全部食管鳞癌患者同步放化疗后的总生存和无进展生存。
  • 对同步放化疗短期疗效好的患者,辅助化疗可能带来无进展生存获益。
  • 短期疗效可能有助于筛选辅助化疗获益人群,尚需前瞻性研究证实。

研究设计与样本

  • 回顾性分析2013年1月至2017年12月共244例临床II-IVa期接受同步放化疗的食管鳞癌患者。
  • 其中同步放化疗联合辅助化疗组131例,单纯同步放化疗组113例。
  • 采用倾向评分匹配(1:1,每组99例)、亚组分析和Cox回归模型分析预测因素。
  • 以总生存和无进展生存为终点。

主要发现

  • 倾向评分匹配后两组总生存无显著差异(HR=1.024;95%CI 0.737-1.423;P=0.886)。
  • 倾向评分匹配后两组无进展生存无显著差异(HR=0.809;95%CI 0.582-1.126;P=0.197)。
  • 短期疗效好的亚组无进展生存更优,且倾向于接受同步放化疗联合辅助化疗(HR=0.542;95%CI 0.336-0.876;P=0.008)。
  • 该亚组的独立预测作用在进一步多因素Cox回归分析中得到确认。

关键数值与推荐

  • 倾向评分匹配后总生存HR=1.024(95%CI 0.737-1.423,P=0.886)。
  • 倾向评分匹配后无进展生存HR=0.809(95%CI 0.582-1.126,P=0.197)。
  • 短期疗效好的亚组无进展生存HR=0.542(95%CI 0.336-0.876,P=0.008)。

临床怎么用

  • 对于接受同步放化疗的食管鳞癌患者,不应常规推荐辅助化疗,需结合短期疗效评估。
  • 同步放化疗后短期疗效好的患者可考虑辅助化疗以改善无进展生存。
  • 短期疗效可作为筛选辅助化疗获益人群的参考指标。

局限性

  • 本研究为回顾性分析,存在选择偏倚等固有局限。
  • 短期疗效预测辅助化疗获益的结论尚需前瞻性研究进一步证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether adjuvant chemotherapy (AC) after concurrent chemoradiotherapy (CCRT) could provide benefit to esophageal squamous cell carcinoma (ESCC) patients is controversial. Therefore, we decided to investigate the potential benefit of AC after CCRT for ESCC and to identify biomarkers predictive of a clinical benefit. METHODS: We retrospectively analysed the clinical data of ESCC patients with clinical stage II-IVa who underwent CCRT. Then, we compared patients who received CCRT and AC (CCRT + AC group) with those who received CCRT alone (CCRT group). Propensity score analysis, subgroup analysis and an additional Cox regression model were conducted to analyse the predictive factors. The overall survival (OS) and progression-free survival (PFS) rates were taken as the endpoints. RESULTS: From January 2013 to December 2017, 244 patients were recruited (n = 131 for CCRT + AC; n = 113 for CCRT alone) for the analysis. After propensity score matching was performed (1:1 and 99 patients for each group) with consideration of the basic clinical characteristics, no significant differences were found in OS (HR = 1.024; 95% CI 0.737-1.423; P = 0.886) or PFS (HR = 0.809; 95% CI 0.582-1.126; P = 0.197) between the two groups. The good short-term response subgroup showed a better PFS and favoured CCRT + AC treatment (HR = 0.542; 95% CI 0.336-0.876; P = 0.008), the independent predictive role of which was confirmed in additional multivariate Cox regression analysis. CONCLUSIONS: Although AC did not significantly improve PFS and OS for all ESCC patients after CCRT, the short-term response to CCRT might help identify a subgroup that will benefit, which needs further prospective research to confirm.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Liu A, Wang Y, Wang X, et al. Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients. Radiat Oncol. 2021. PMID: 34600574. doi:10.1186/s13014-021-01921-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。